Common Use

Ranexa is a prescription antianginal medication containing ranolazine, a first-in-class late sodium current inhibitor specifically approved for the treatment of chronic angina (persistent, recurring chest pain caused by insufficient blood flow and oxygen supply to the heart muscle). Unlike traditional angina medications such as beta-blockers, calcium channel blockers, and nitrates that work primarily by reducing heart rate, lowering blood pressure, or dilating coronary arteries, ranolazine operates through a unique and innovative pharmacological mechanism. It selectively inhibits the late phase of the inward sodium current (late INa) in cardiac muscle cells — an abnormal current that becomes enhanced during myocardial ischemia (reduced blood flow to the heart). By blocking this late sodium current, ranolazine prevents the pathological intracellular sodium overload that occurs during ischemic episodes, which in turn reduces excessive calcium influx through the sodium-calcium exchanger. This cascade of effects decreases the mechanical tension, oxygen demand, and diastolic stiffness of the ischemic heart muscle, effectively reducing the frequency, severity, and duration of angina episodes without significantly affecting heart rate or blood pressure. When you buy Ranexa online from our pharmacy, you access a clinically proven heart medication that can be used as first-line monotherapy for chronic angina or as valuable add-on therapy when traditional antianginal agents alone do not provide adequate chest pain control. As a Ranexa generic equivalent, ranolazine delivers the same evidence-based angina treatment benefits at a more affordable and accessible price. Clinical trials have consistently demonstrated that ranolazine significantly reduces the frequency of weekly angina episodes, decreases nitroglycerin consumption, and improves exercise tolerance and duration in patients with chronic stable angina — making it an essential component of comprehensive angina management for patients who continue to experience limiting chest pain despite conventional therapy.

Dosage and Direction

Take Ranexa orally, usually twice daily, with or without food, as prescribed by your healthcare provider. The recommended starting dose of ranolazine is 500 mg twice daily, which may be increased to the maximum recommended dose of 1000 mg twice daily based on your clinical response, symptom control, and tolerability. Swallow the extended-release tablet whole with a full glass of water — do not crush, chew, break, or split the tablet, as destroying the extended-release formulation will cause the entire dose to be released at once, potentially leading to dangerous peak blood levels and increased risk of QT prolongation and other adverse effects. Take each dose at approximately the same times each day (typically morning and evening, approximately 12 hours apart) to maintain consistent therapeutic blood levels and sustained antianginal protection throughout the entire 24-hour period. Your doctor will determine the most appropriate dose based on your angina severity, frequency of chest pain episodes, concurrent medications (particularly those that may interact with ranolazine), and liver and kidney function. It is important to understand that Ranexa is prescribed for the ongoing management of chronic stable angina — it is not a rescue medication for acute angina attacks. Continue using your short-acting nitroglycerin (sublingual tablets or spray) for breakthrough acute chest pain episodes as directed by your cardiologist. Do not abruptly discontinue ranolazine without medical guidance, and report any increase in angina frequency or severity to your healthcare provider promptly.

Precautions

Before you buy ranolazine or begin Ranexa therapy, inform your healthcare provider comprehensively about your medical history and all current medications. Pay particular attention to disclosing any liver disease or hepatic impairment (ranolazine is extensively metabolized by the liver, and impaired hepatic function can lead to dangerously elevated drug levels), kidney disease or impaired renal function, a personal or family history of QT prolongation or long QT syndrome, any cardiac arrhythmia or conduction disorder, electrolyte imbalances (particularly low potassium or magnesium), or a history of heart failure. Ranolazine can cause dose-dependent prolongation of the QT interval on the electrocardiogram (ECG), which increases the risk of potentially fatal cardiac arrhythmias — your doctor may order a baseline ECG before starting treatment and may repeat it periodically during therapy, particularly after dose increases. Avoid consuming grapefruit or grapefruit juice during Ranexa treatment, as grapefruit inhibits the CYP3A4 enzyme system that metabolizes ranolazine, potentially increasing drug blood levels to a dangerous degree and amplifying the risk of QT prolongation and other side effects. Maintain adequate hydration and balanced electrolyte levels throughout treatment, as hypokalemia (low potassium) and hypomagnesemia (low magnesium) can independently prolong the QT interval and compound the arrhythmia risk associated with ranolazine. Dizziness, lightheadedness, and occasionally syncope (fainting) have been reported with ranolazine — exercise caution when driving, operating machinery, or performing activities requiring full alertness until you understand how this medication affects you personally. If you are pregnant, planning pregnancy, or breastfeeding, consult your healthcare provider before using Ranexa, as the safety of ranolazine during pregnancy and lactation has not been adequately established in humans.

Contraindications

Do not use Ranexa if you have severe hepatic impairment (Child-Pugh Class C), as the liver is the primary organ responsible for ranolazine metabolism, and severe liver dysfunction leads to markedly elevated and unpredictable drug levels that significantly increase the risk of QT prolongation, cardiac arrhythmias, and other serious adverse effects. Ranolazine is strictly contraindicated for concurrent use with strong CYP3A4 inhibitors — including ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, nelfinavir, and saquinavir — as these drugs dramatically increase ranolazine blood concentrations, greatly amplifying the risk of dangerous QT prolongation and potentially fatal cardiac arrhythmias (torsades de pointes). Similarly, strong CYP3A4 inducers such as rifampin, phenobarbital, carbamazepine, phenytoin, and St. John's Wort are contraindicated, as they significantly reduce ranolazine blood levels and therapeutic efficacy. Do not use Ranexa if you have a known allergy or hypersensitivity to ranolazine or any inactive ingredient in the formulation. This antianginal medication is not indicated or approved for the treatment of acute angina episodes or acute coronary syndrome — it is designed exclusively for the chronic management of stable angina. Ranexa generic formulations carry all identical contraindications. Patients with clinically significant pre-existing QT prolongation, congenital long QT syndrome, or those currently taking other QT-prolonging medications should use ranolazine only under careful specialist supervision with ECG monitoring, if at all — as the additive QT-prolonging effects may create an unacceptable arrhythmia risk.

Possible Side Effect

Common side effects of ranolazine include dizziness (the most frequently reported adverse event), constipation, headache, nausea, and mild to moderate asthenia (weakness or fatigue). These effects are generally dose-related, mild in severity, and tend to improve or resolve as your body adjusts to the medication over the first few weeks of treatment. Constipation is relatively common with ranolazine and can usually be managed with adequate fluid intake, dietary fiber, and mild laxatives if needed. The most clinically significant pharmacological effect of ranolazine is dose-dependent QT interval prolongation on the ECG — while this is usually modest (average prolongation of approximately 2-7 milliseconds at therapeutic doses), it becomes clinically important in patients with pre-existing QT prolongation, electrolyte imbalances, or those taking other QT-prolonging medications, as it increases the theoretical risk of potentially life-threatening ventricular arrhythmias including torsades de pointes. Less common side effects include dry mouth, vomiting, abdominal pain, peripheral edema (mild ankle swelling), blurred vision, tinnitus (ringing in the ears), vertigo, and tremor. Small, clinically insignificant increases in serum creatinine may occur (due to inhibition of tubular creatinine secretion rather than actual kidney damage) and do not typically require dose adjustment or treatment discontinuation. Ranolazine may also cause small elevations in HbA1c in non-diabetic patients, though the clinical significance of this finding is unclear. Rare but serious adverse effects include clinically significant cardiac arrhythmias, syncope (fainting), angioedema, acute renal failure (in patients with pre-existing severe kidney impairment), and pancytopenia. Seek immediate medical attention if you experience heart palpitations or awareness of irregular heartbeat, severe dizziness or fainting, persistent or worsening chest pain, severe constipation or abdominal distension, signs of allergic reaction (rash, swelling, difficulty breathing), or any new or unexplained symptoms during your angina treatment.

Drug Interaction

Ranexa has numerous and clinically significant drug interactions that must be carefully managed for patient safety. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, nelfinavir, lopinavir, saquinavir, and nefazodone) are strictly contraindicated as they can increase ranolazine blood levels by 3 to 4 fold, creating a serious risk of excessive QT prolongation and potentially fatal arrhythmias. Moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, fluconazole, and aprepitant) significantly increase ranolazine exposure — when co-administration is necessary, the ranolazine dose should be limited to a maximum of 500 mg twice daily, and patients should be closely monitored. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, phenobarbital, and St. John's Wort) are contraindicated as they substantially reduce ranolazine levels and therapeutic effectiveness. Ranolazine is itself a moderate inhibitor of CYP3A4, CYP2D6, and P-glycoprotein (P-gp), and can increase the blood levels of several important medications: it can increase simvastatin exposure (limit simvastatin to 20 mg daily), increase digoxin levels (requiring monitoring and possible dose reduction), and increase the exposure of CYP2D6 substrates including metoprolol, tricyclic antidepressants, and antipsychotics. The combination of ranolazine with other QT-prolonging drugs — including Class Ia and III antiarrhythmics (quinidine, sotalol, amiodarone, dofetilide), certain antipsychotics, certain fluoroquinolone antibiotics, and ondansetron — requires extreme caution and specialist oversight due to the additive risk of dangerous QT prolongation. Ranolazine increases metformin exposure by inhibiting the OCT2 renal transporter — metformin dose may need to be limited to 1700 mg daily when used concurrently. Cyclosporine and tacrolimus levels may be increased by ranolazine. Always provide your cardiologist, prescribing physician, and pharmacist with a complete and current list of all medications, including prescription drugs, over-the-counter products, vitamins, supplements, and herbal preparations, before starting or modifying your Ranexa therapy.

Missed Dose

If you miss a dose of Ranexa, take it as soon as you remember. However, if it is already almost time for your next scheduled dose (within a few hours), skip the missed dose entirely and continue with your regular twice-daily dosing schedule — do not take two doses at once or within a short time interval to compensate, as this could lead to elevated drug levels and an increased risk of QT prolongation and other dose-related side effects. Consistent twice-daily dosing is important for maintaining stable therapeutic ranolazine levels and providing continuous antianginal protection throughout each 24-hour period. If you frequently miss doses, consider practical adherence strategies such as setting morning and evening phone alarms, using a pill organizer, associating each dose with a consistent daily routine (such as meals or brushing your teeth), or using a medication tracking application. Contact your healthcare provider if you notice an increase in angina frequency or worsening of chest pain that may be related to inconsistent medication use or missed doses.

Overdose

In case of suspected or confirmed Ranexa overdose, seek immediate emergency medical attention. Symptoms of ranolazine overdose may include severe and prolonged dizziness, syncope (fainting), significant QT prolongation with the potential for dangerous ventricular arrhythmias (including torsades de pointes and ventricular fibrillation), marked hypotension, confusion, diplopia (double vision), paresthesia (tingling or numbness), severe nausea and vomiting, and potentially cardiac arrest in extreme cases. Limited clinical experience exists with massive ranolazine overdose, but based on the drug's pharmacological profile, the primary concern is dose-dependent and potentially life-threatening QT prolongation leading to fatal cardiac arrhythmias. There is no specific antidote for ranolazine overdose. Treatment is supportive and symptomatic, with an emphasis on continuous ECG monitoring for cardiac rhythm disturbances, correction of electrolyte abnormalities (particularly potassium and magnesium), hemodynamic support with intravenous fluids and vasopressors as needed, and cardiovascular monitoring for an extended period (ranolazine's extended-release formulation means drug levels may remain elevated for longer than expected). Hemodialysis is unlikely to significantly accelerate ranolazine elimination due to the drug's high protein binding and large volume of distribution. Activated charcoal may be considered if the patient presents within 1-2 hours of ingestion.

Storage

Store Ranexa at controlled room temperature between 20°C and 25°C (68°F to 77°F), with brief temporary excursions permitted between 15°C and 30°C (59°F to 86°F). Protect the extended-release tablets from moisture, excessive heat, and direct light exposure, as these conditions may compromise the integrity of the extended-release coating and the chemical stability of ranolazine. Keep the tablets in their original packaging or container, tightly sealed, and with any desiccant packets left in place. Do not store this heart medication in the bathroom, kitchen, vehicle, or any environment with significant temperature or humidity fluctuations. Keep Ranexa and all cardiovascular medications well out of reach of children and household pets. Do not use tablets that are past their expiration date or that show visible signs of damage, discoloration, or moisture exposure. Dispose of expired or unused ranolazine tablets safely and responsibly — consult your pharmacist about recommended disposal methods, participate in local medication take-back programs, or follow applicable guidelines for environmentally responsible prescription medication disposal.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.